Virus du papillome humain (VPH)
Canadian Immunization Guide: Evergreen Edition
Evergreen edition presents information on the immunizing agents available in Canada and their use in the prevention of communicable diseases.
Guide canadien d'immunisation : Edition évolutive
Le présent Guide (édition évolutive) contient des renseignements sur les agents immunisants disponibles au Canada et sur leur utilisation en vue de prévenir les maladies transmissibles.
Cost-effectiveness of sex-neutral HPV vaccination in Sweden, accounting for herd immunity and sexual behaviour
The aim was to assess cost-effectiveness of expanding the Swedish HPV-vaccination program to include preadolescent boys, by comparing health effects and costs of HPV-related disease, with a sex-neutral vaccination program versus only vaccinating girls.
Human papillomavirus vaccine for children and adolescents: CPS Position Statement
Human papillomavirus (HPV) is known to cause genital warts, cervical cancer, penile cancer, anal cancer and oropharyngeal cancer. In North America, the lifetime cumulative incidence of HPV infection is estimated at more than 70% for all HPV types combined. A safe and effective vaccine against nine HPV types is available. HPV vaccine should be administered routinely to all girls and boys between the ages of 9 and 13 years of age. All youth who have not received the vaccine in a routine program should receive the vaccine in a ‘catch-up’ program. Physicians caring for children and youth should advocate for funding and implementation of universal HPV vaccine programs.
Le vaccin contre le virus du papillome humain chez les enfants et les adolescents : Document de principes de la SCP
On sait que le virus du papillome humain (VPH) cause des condylomes (des verrues génitales), le cancer du col de l’utérus, le cancer du pénis, le cancer anal et le cancer oropharyngé. En Amérique du Nord, l’incidence cumulative de l’infection par le VPH au cours de la vie est évaluée à plus de 70 % pour tous les types de VPH combinés. Un vaccin sécuritaire et efficace est offert contre neuf types de VPH. Le vaccin contre le VPH doit être administré systématiquement à l’ensemble des filles et des garçons âgés de neuf à 13 ans. Tous les jeunes qui n’ont pas été vaccinés dans le cadre d’un programme systématique devraient participer à un programme de rattrapage. Les médecins qui soignent des enfants et des adolescents devraient préconiser le financement et la mise en œuvre de programmes de vaccination universels contre le VPH.
Examen de la documentation du CCNI concernant l'immunisation contre le VPH des populations immunodéprimées
Les populations immunodéprimées présentent un risque accru d'être infectées par le virus du papillome humain (VPH) et de développer des cancers liés à cette maladie. Toutefois, d'autres précisions sont requises concernant l'immunogénicité et les résultats liés à l'innocuité de l'immunisation contre le VPH dans les populations immunodéprimées. Afin de remédier à cette lacune, une question de recherche a été élaborée par le groupe de travail sur le VPH du Comité consultatif national de l'immunisation (CCNI) et utilisée pour orienter une analyse documentaire.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. Researchers aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years.
Human papillomavirus (HPV) (US CDC)
Provides information for parents, for health care professionals, and for partners and programs on HPV: prevention, screening, signs and symptoms, vaccinations, HPV vaccine safety, treatment, and the link between HPV and cancer.
Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey
Human papillomavirus (HPV), a sexually transmitted infection, can cause anogenital warts and a number of cancers. To prevent morbidity and mortality, three vaccines have been licensed and are recommended by Canada’s National Advisory Committee on Immunisation (for girls since 2007 and boys since 2012). Nevertheless, HPV vaccine coverage in Canada remains suboptimal in many regions. This study will be the first to concurrently examine the correlates of HPV vaccine decision-making in parents of school-aged girls and boys and evaluate changes in parental knowledge, attitudes and behaviours over time.
NACI Literature Review for HPV Immunization of Immunocompromised Populations
Immunocompromised populations are at increased risk for HPV infection and for developing HPV-associated cancers. However, additional clarity is required surrounding the immunogenicity and safety outcomes of HPV immunization for immunocompromised populations. To address this information gap, a research question was developed by the National Advisory Committee on Immunization (NACI) human papillomavirus (HPV) Working Group and used to guide a literature review.